(XHE) SPDR S&P Health Care - Ratings and Ratios
Medical Devices, Equipment, Supplies, Diagnostics, Tools
Description: XHE SPDR S&P Health Care
The SPDR S&P Health Care Equipment ETF (XHE) is designed to mirror the performance of the S&P Health Care Equipment Select Industry Index. To achieve this, the fund adopts a sampling strategy, investing at least 80% of its total assets in the securities that comprise the index, effectively replicating the health care equipment segment of the broader S&P Total Market Index (S&P TMI).
The health care equipment sector is a critical component of the healthcare industry, encompassing companies involved in the production of medical equipment and devices. This includes a wide range of products from surgical instruments and diagnostic equipment to medical implants and monitoring devices. The funds focus on this specific segment allows investors to target their investments towards the healthcare equipment industry, potentially capitalizing on trends and growth opportunities within this niche.
From a technical analysis perspective, examining the moving averages indicates a potential trend reversal. With the SMA20 (78.75) and SMA50 (80.41) being lower than the current price (82.75), it suggests a short-term uptrend. However, the SMA200 (87.35) is significantly higher, indicating a longer-term downtrend. The Average True Range (ATR) of 2.36, or 2.86%, signifies moderate volatility, suggesting that while there are fluctuations, they are not extreme. Considering the 52-week high (95.73) and low (72.34), the current price is roughly mid-range, suggesting potential for both upward and downward movement.
Fundamentally, the Assets Under Management (AUM) of $177.22M USD indicate a relatively smaller ETF, which can sometimes result in lower liquidity and potentially higher volatility. However, it also signifies a focused investment vehicle that is specifically targeting the healthcare equipment sector, potentially appealing to investors looking for niche exposure.
Forecasting the future performance of XHE involves considering both the technical and fundamental data. Given the current technical indicators and the fundamental focus of the ETF, a potential forecast could involve a cautious optimism in the short term due to the uptrend indicated by the SMA20 and SMA50. However, the longer-term downtrend suggested by the SMA200 and the moderate volatility indicated by the ATR should temper expectations. Investors should monitor the AUM for signs of significant inflows or outflows, which could impact liquidity and volatility. A break above the SMA200 could signal a longer-term uptrend, while a drop below the 52-week low could indicate further declines. Thus, a balanced view, taking into account both technical trends and fundamental data, is essential for making informed investment decisions regarding XHE.
Additional Sources for XHE ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
XHE ETF Overview
Market Cap in USD | 164m |
Category | Health |
TER | 0.35% |
IPO / Inception | 2011-01-26 |
XHE ETF Ratings
Growth Rating | -38.2 |
Fundamental | - |
Dividend Rating | 36.5 |
Rel. Strength | -17.7 |
Analysts | - |
Fair Price Momentum | 74.95 USD |
Fair Price DCF | - |
XHE Dividends
Dividend Yield 12m | 0.04% |
Yield on Cost 5y | 0.03% |
Annual Growth 5y | 100.00% |
Payout Consistency | 45.4% |
Payout Ratio | % |
XHE Growth Ratios
Growth Correlation 3m | 48.3% |
Growth Correlation 12m | -49.4% |
Growth Correlation 5y | -75% |
CAGR 5y | -2.19% |
CAGR/Max DD 5y | -0.04 |
Sharpe Ratio 12m | 0.53 |
Alpha | -18.43 |
Beta | 0.714 |
Volatility | 22.12% |
Current Volume | 14.9k |
Average Volume 20d | 9.1k |
Stop Loss | 77.2 (-3.4%) |
As of July 14, 2025, the stock is trading at USD 79.95 with a total of 14,860 shares traded.
Over the past week, the price has changed by +0.02%, over one month by -0.14%, over three months by +4.40% and over the past year by -7.44%.
Probably not. Based on ValueRay´s Analyses, SPDR S&P Health Care (NYSE ARCA:XHE) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -38.21 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XHE is around 74.95 USD . This means that XHE is currently overvalued and has a potential downside of -6.25%.
SPDR S&P Health Care has no consensus analysts rating.
According to our own proprietary Forecast Model, XHE SPDR S&P Health Care will be worth about 85.9 in July 2026. The stock is currently trading at 79.95. This means that the stock has a potential upside of +7.4%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 85.9 | 7.4% |